-
Zai Lab and Entasis Therapeutics announce positive key results of SUL-DUR Phase 3 clinical study ATTACK
Time of Update: 2021-11-04
In patients with carbapenem-resistant Acinetobacter infection (CRABC m-MITT [1] population of the study in Part A), SUL-DUR treatment reached the main study endpoint of 28-day all-cause mortality, indicating that there is more Compared with colistin, SUL-DUR treatment has statistically significant non-inferiority .
-
Sansheng Guojian SSGJ-706 was approved by the FDA to enter Phase I-II clinical trials
Time of Update: 2021-11-04
On October 18th, Sansheng Guojian issued an announcement stating that the company's SSGJ-706 treatment of advanced solid tumors, relapsed or refractory lymphomas has been approved by the US FDA to ent
-
The Fortune Global 500 Summit was held in Hangzhou, Guangyao Li Chuyuan: Fulfilling the Mission of Traditional Chinese Medicine for Human Health
Time of Update: 2021-11-04
Li Chuyuan introduced the practices and responsibilities of Guangzhou Pharmaceutical Group in fighting the epidemic, and focused on the important role played by Chinese medicine in global health .
-
A breakthrough in Yangtze River's proprietary Chinese medicines!
Time of Update: 2021-11-04
Figure 1: New drugs declared by Yangtze River since 2021Source: CDE official websiteFigure 2: Clinical progress of new drugsSource: China Drug Clinical Trial Publicity Library of MeinenetSince the beginning of this year, Yangtze River has applied for clinical application of 3 new drugs: the indication is analgesic chemical medicine Class 1 new drug YR-1702 injection and the indication is seasonal allergic rhinitis Chinese medicine Class 2.
-
Approval of innovative drugs continues to accelerate, with more than 25 domestically-made new drugs on the market
Time of Update: 2021-11-04
Another example is Huahai Pharmaceutical's research and development investment accounted for more than 10% of revenue in recent years.
Data show that from 2016 to 2019, the market size of China's innovative drug industry increased from US$113.
-
In the context of AI, drug R&D innovation is accelerating
Time of Update: 2021-11-04
Some time ago, Huawei also released the "Huawei Cloud Pangu" drug molecular model, which is a new breakthrough for Huawei to enter the field of AI-assisted drug research and development .
-
Nuocheng Jianhua won the Kunpeng Award of "2021 Best Original Small Molecule Chemical Drug TOP3 Enterprise"
Time of Update: 2021-11-04
Beijing, October 20, 2021/PRNewswire/ - The "2021 Nanjing International New Medicine and Life and Health Industry Innovation Investment Summit" hosted by the Nanjing Municipal Government released today the second "2021 China Biomedical Industry Chain Innovation Billboard" .
-
The conditioning of traditional Chinese medicine ointment formula is favored by experts: one person must be "tailored"
Time of Update: 2021-11-04
Experts pointed out that as people's awareness of health care increases, the demand for traditional Chinese medicine ointment is gradually increasing.
Experts pointed out that as people's awareness of health care increases, the demand for traditional Chinese medicine ointment is gradually increasing.
-
A quick look at the news about foreign "medicine" this month
Time of Update: 2021-11-04
A quick overview of key foreign drug news this month: Roche T drug was approved to treat early lung cancer; FDA approved Merck K drug combined with chemotherapy for first-line treatment of cervical cancer; AstraZeneca Imfinzi combined with tremelimumab to treat liver cancer phase 3 clinical end; Eli Lilly Verzenio was awarded FDA approved the treatment of early breast cancer .
-
Boehringer Ingelheim supported the finalists for the cross-border design of "Every second and every second, the whole family" was announced
Time of Update: 2021-11-04
Shanghai, October 21, 2021/PRNewswire/ - The call for papers for the cross-industry design of home furnishings, culture and creativity, which lasted for half a month, was launched by the World Stroke Organization (WSO) The international communication theme of "Minutes can save lives" on World Stroke Day in 2021[1], while integrating the "Stroke 120" mantra or "BE FAST" mantra, and keywords such as "stroke, family, care, rescue, first aid", etc.
-
Osaikon's subsidiary zoledronic acid concentrated solution for injection obtained the notification of acceptance of the listing application
Time of Update: 2021-11-04
On October 21, Osaikang issued an announcement stating that its wholly-owned subsidiary, Jiangsu Osaikang, had recently received the "Notice of Acceptance" for the marketing application for concentrated zoledronic acid solution for injection issued by the National Medical Products Administration .
-
You can't play with the full variety of Chinese herbal medicine
Time of Update: 2021-11-04
Traditional Chinese medicine is also a typical non-standard product, which can be large or small, long or segmented, round or flat, or old and new; how can you effectively control quality at low cost?This is a naked challenge to the scientific management of industrialization!
-
Tasly's subsidiary bezafibrate sustained-release tablets and temozolomide for injection obtained drug registration certificates
Time of Update: 2021-11-04
On October 21, Tasly issued an announcement stating that its subsidiaries, bezafibrate sustained-release tablets and temozolomide for injection, have obtained drug registration certificates .
Sustained-release bezafibrate tablets are used to treat adult hypertriglyceridemia and mixed hyperlipidemia .
-
Target EGFR×HER3!
Time of Update: 2021-11-04
ArticleMedicine GuanlanAccording to information published on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, the BL-B01D1 for injection declared by Bailey Pharmaceutical has obtained a clinical implied license and is intended to be developed for the treatment of locally advanced or metastatic epithelial tumors .
-
Shandong and Shanxi alliance cut drug prices: 50 drugs fell by more than 92%
Time of Update: 2021-11-04
On October 19, the results of the second batch of (Lu-Jin Alliance) drug centralized procurement in Shandong Province were announced .
This time the Lu-Jin alliance gathered, patients in Shandong and Shanxi provinces will soon use the reduced-price medicines .
-
With the general rise in the performance of the third quarterly reports of medical companies, they are still facing severe performance tests
Time of Update: 2021-11-04
613 billion yuan and net profit attributable to shareholders of listed companies of 2.
It is worth noting that since its listing in October 2018, Mindray Medical's single-quarter net profit growth rate has continued to remain above 20% .
-
The new fully human VH antibody fragment ZL-1102 developed internally by Zai Lab for the clinical phase 1b study of psoriasis reached a proof of concept
Time of Update: 2021-11-04
(Nasdaq stock code: ZLAB; Hong Kong Stock Exchange stock code: 9688), a patient-centric company in the commercialization stage The innovative global biopharmaceutical company today announced the positive key results of a randomized, double-blind, placebo-controlled, first-in-human clinical Phase 1b proof-of-concept study designed to evaluate the topical use of ZL-1102 The safety, pharmacokinetic properties and efficacy of adult patients with mild to moderate chronic plaque psoriasis (CPP) .
-
Under the general trend of innovation in the pharmaceutical industry, the approval of domestically produced innovative drugs is showing a blowout trend
Time of Update: 2021-11-04
According to data, the approval of domestically-made innovative drugs for the market this year is showing a blowout trend .
According to the current trend, the industry believes that in the next 2-3 years, there will be more than 20 PD-1 products on the global market, while 15 PD-1 products on the domestic market will become increasingly fierce .
-
Hebo Medicine Bartolizumab completes the first patient's administration for Phase II trial of thyroid ophthalmopathy
Time of Update: 2021-11-04
HK) recently announced its fully human anti-FcRn antibody Bartoli The phase II clinical trial of monoclonal antibody (HBM9161) for thyroid eye disease has completed the first administration of the first subject .
-
Development Pharmaceuticals PD-L1/TGF-β dual target antibody obtained clinical trial license in China
Time of Update: 2021-11-04
HK, hereinafter referred to as "Kaifeng Pharmaceutical") is pleased to announce that PD-L1/ The TGF-β dual target antibody (GT90008) has been approved by the National Medical Products Administration (NMPA) of China today to carry out clinical trials for the treatment of advanced solid tumors .
